SERUM MIR-195, MIR-501 COMBINED WITH MULTI-MODALITY MRI IN THE EVALUATION OF CERVICAL CANCER PROGNOSES WITH SYNCHRONOUS CHEMOTHERAPY

Meixian Deng^1#, Wei Liu^2#*

¹Department of Obstetrics and Gynecology, Fifth Hospital in Wuhan, Wuhan 430080, PR China - ²Department of Radiology, China Resources & WISCO General Hospital, Wuhan 430080, PR China

Objective: The purpose of this study was to explore the specific application effect of serum miR-195, miR-501 combined with multimodal MRI in the evaluation of cervical cancer prognoses with synchronous chemotherapy.

Method: This study selected 40 cases of mid-advanced cervical cancer treated in our hospital. Cancer patients were the research subjects and simultaneous chemotherapy was the treatment method. All cervical cancer patients underwent routine pelvic MRI examination and serum miR-195 and miR-501 factor determination on the 10^th day after the start of concurrent radiochemotherapy and 1 month after the end of chemotherapy. Patients were followed up 6-12 months after treatment and cervical cancer MRI examinations were performed.

Results: The results showed that, after the simultaneous radiotherapy and chemotherapy of cervical cancer, serums miR-195 and miR-501 combined with multimodal MRI using ADC1000 and CYFRA21 had a higher prognostic efficacy. The tumor detection curve area was AGC = 0.924, 96%CI: 0.836-1.200. The average ADC value after radiotherapy was (2.078±0.245) × 10-3 mm2/s and the minimum ADC value was (1.939±0.083) × 10-3 mm2/s.

Conclusion: Serum miR-195, miR-501 combined with multimodal MRI can be used to efficiently and accurately evaluate the efficacy and prognosis of concurrent radiotherapy and chemotherapy for advanced cervical cancer.